medigraphic.com
ISSN 1405-1710 (Print)

2019, Number 3

Next >>

Rev Cent Dermatol Pascua 2019; 28 (3)

Index for measuring speed of progression of non-segmental vitiligo (pilot study)

Peralta-Pedrero ML, Morales-Sánchez MA, Jurado Santa-Cruz F, Guerrero-Oliva G, Chirino-Castillo GQ, Cruz-Avelar A

Language: Spanish
References: 13
Page: 113-116
PDF size: 335.57 Kb.


ABSTRACT

Background: Vitiligo is the most frequent acquired dyschromia, affecting 0.5 to 2% of the world’s population. There is no quantitative method to measure the speed of progression. Methods: Cross-sectional study in the Dermatological Center «Dr. Ladislao de la Pascua». Patients 18 years of age and older, with non-segmental vitiligo were included. The affected body surface was determined with Vitiligo Extent Score (VES). The index that we propose is the «annual progression rate» that is defined as the ratio of the affected body surface calculated with the VES instrument divided by the years that the patient has lived with non-segmental vitiligo (formula: VES/evolution time). Results: 84 patients with age 43 ± 15 (18-80) years participated, predominantly the female gender n = 47 (56%). The «annual progression rate» was: [md (P25-75) R] 0.15% (0.05-0.39) from 0 to 4.5%. It was observed that the dissemination is close to 1% annually in the 90th percentile, only eight patients presented an extremely rapid progression, with a maximum of 4.5% of affected body surface area per year. Conclusion: In future studies the monthly or annual progression rate can be a useful tool to identify prognostic factors and even for clinical trials. Studies with large samples are required to establish normative values of the progression rate.


REFERENCES

  1. Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y et al. The prevalence of vitiligo: a meta-analysis. PLoS One. 2016; 11: e0163806.

  2. van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V et al. Development and validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. J Invest Dermatol. 2016; 136: 978-984.

  3. van Geel N, Grine L, De Wispelaere P, Mertens D, Prinsen CAC, Speeckaert R. Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019; 33: 1667-1675.

  4. González U, Whitton M, Eleftheriadou V, Pinart M, Batchelor J, Leonardi-Bee J. Guidelines for designing and reporting clinical trials in vitiligo. Arch Dermatol. 2011; 147: 1428-1436.

  5. Vrijman C, Linthorst-Homan MW, Limpens J, van der Veen W, Wolkerstorfer A, Terwee CB et al. Measurement properties of outcome measures for vitiligo. A systematic review. Arch Dermatol. 2012; 148: 1302-1309.

  6. Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol. 2012; 167: 804-814.

  7. Anyanwu C, Langenhan J, Werth VP. Measurement of disease severity in cutaneous autoimmune diseases. F1000Prime Rep. 2013; 5: 19.

  8. Eleftheriadou V. Future horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review ‘Interventions for vitiligo’ 2010. Br J Dermatol. 2013; 169 Suppl 3: 67-70.

  9. Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T et al. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res. 2015; 28: 363-369.

  10. Peralta-Pedrero ML, Jurado Santa-Cruz F. What we know about the Clinical Course of Nonsegmental Vitiligo: experience of a researcher and a dermatologist. Actas Dermosifiliogr. 2018; 109: 767-770.

  11. Peralta-Pedrero ML, Morales-Sánchez MA, Jurado-Santa Cruz F, De la Torre-García ME, Cruz-Peralta ES, Olguín-García MG. Systematic review of clinimetric instruments to determine the severity of non-segmental vitiligo. Australas J Dermatol. 2019; 60: e178-e185.

  12. Sosa JJ, Currimbhoy SD, Ukoha U, Sirignano S, O’Leary R, Vandergriff T et al. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo. J Am Acad Dermatol. 2015; 73: 272-275.

  13. Zhang L, Chen S, Kang Y, Wang X, Yan F, Jiang M et al. Association of clinical markers with disease progression in patients with vitiligo from China. JAMA Dermatol. 2020. doi: 10.1001/jamadermatol.2019.4483.




2020     |     www.medigraphic.com